Bausch Health Companies Inc. (NYSE:BHC) Given Consensus Recommendation of “Reduce” by Brokerages

Bausch Health Companies Inc. (NYSE:BHC) has received an average rating of “Reduce” from the seven research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $7.17.

A number of brokerages have weighed in on BHC. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Thursday. Royal Bank of Canada lowered their price target on Bausch Health Companies from $9.00 to $8.50 and set a “sector perform” rating for the company in a report on Monday, April 7th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th.

Hedge Funds Weigh In On Bausch Health Companies

Several hedge funds and other institutional investors have recently made changes to their positions in BHC. Mountain Hill Investment Partners Corp. purchased a new position in Bausch Health Companies in the fourth quarter valued at about $56,000. Wealthquest Corp purchased a new stake in shares of Bausch Health Companies during the 1st quarter valued at about $58,000. Bank of Nova Scotia purchased a new stake in shares of Bausch Health Companies during the 4th quarter valued at about $83,000. One68 Global Capital LLC acquired a new position in Bausch Health Companies during the 4th quarter worth approximately $90,000. Finally, Balyasny Asset Management L.P. purchased a new position in Bausch Health Companies in the 4th quarter worth approximately $97,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Trading Down 4.2 %

Shares of NYSE BHC opened at $5.28 on Friday. The company’s 50-day moving average price is $6.14 and its 200 day moving average price is $7.26. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $9.85. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -44.00, a PEG ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. As a group, research analysts expect that Bausch Health Companies will post 4.41 earnings per share for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.